Press release
Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.
Dexcom G7 is now cleared in the U.S. for people with all Types of diabetes ages two years and older, giving more people than ever access to a powerfully
About this update from Dexcom, Inc.
[{"type":"text","content":"\n\nDexcom G7 is now cleared in the U.S. for people with all Types of diabetes ages two years and older, giving more people than ever access to a powerfully simple diabetes management solution\n\n\nWith an overall MARD of 8.2%, Dexcom G7 is the most accurate CGM cleared by the FDA,1 building on the trusted performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia and increase time in range2,3\n\n\nCleared as an integrated continuous glucose monitoring (iCGM) system, Dexcom G7 will be part of the most connected CGM ecosystem in the world,1 with real-time connectivity that can drive integrated insulin delivery systems, connect with wearables like the Apple Watch and integrate with popular digital health apps*\n\n\nAs the number one covered CGM on the market,4 most Dexcom users pay less than those using other CGM systems1\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nDexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with all Types of diabetes ages two years and older.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005302/en/Dexcom G7 now offers a more powerful and easier to use system with a small, all-in-one wearable with no fingersticks or scanning required. (Photo: Business Wire)\n“There’s a reason Dexcom has the best-selling real-time CGM on the market,” said Kevin Sayer, chairman, president and CEO of Dexcom. “For more than a decade, we’ve pioneered generation after generation of sensing technology that consistently delivers improved accuracy, reliability and a simpler user experience, giving people greater control of their diabetes. When we set out to design G7, our goal was simple: to make the most powerful, easy-to-use CGM available for people with diabetes, whether they have Type 1 or Type 2. G7 delivers squarely on that promise. And now that it has been cleared by the FDA, we look forward to making G7 commercially available in the coming months.”\n\n\n\nNew features with Dexcom G7:\n\n\n\n60% smaller, all-in-one, discreet† wearable, easier to use with fewer components\n\n\n30-minute sensor warmup, fastest of any CGM on the market‡\n\n\n12-hou...